IL6 is a known mediator of the pathogenic processes associated with a broad range of autoimmune and inflammatory diseases, and IL6R is the target of the therapeutic agent, tocilizumab, which has been shown to be efficacious in treating multiple autoimmune diseases, including JIA [45]. The gene discussed is IL6R; the disease is juvenile idiopathic arthritis.